|
Compounds for Therapeutic Intervention of Neurofibroma type 1
Compounds for Therapeutic
Intervention of NF Type 1
(CHMC Ref. Id: 2007-0702)
Overview:
Loss of function mutations in the Neurofibromatosis type 1 (NF1) gene result
in an autosomal dominant disease that affects approximately 1 of every 3500 live
births. Ninety-five percent of patients develop neurofibromas, benign Schwann
cell tumors that can associate...
Published: 12/4/2012
Category(s): Therapeutics
|
|
Novel Blood-Brain-Barrier Targeted Protein Delivery
Novel Blood-Brain-Barrier
Targeted Protein Delivery
(CHMC Ref. Id: 2010-1203)
Overview:
The efficacy of therapeutic proteins for brain disorders is restricted due to
the limited ability of these neurotherapeutics to cross the blood brain barrier
(BBB). This technology reports a novel and non-invasive approach for
neuro-therapeutics to cross the...
Published: 12/4/2012
Category(s): Therapeutics
|
|
Indolamine 2,3-Deoxygenase (IDO) as a Therapeutic Target in Leishmaniasis and Tuberculosis
Indolamine 2,3-Deoxygenase
(IDO) as a Therapeutic Target in Leishmaniasis and
Tuberculosis
(CHMC Ref. Id: 2007-1006)
Overview:
Leishmania major is a protozoan pathogen responsible for the disease
leishmaniasis. It is spread through sandflies and it currently affects 12
million people in 88 countries, including an ongoing epidemic in India, Sudan...
Published: 12/4/2012
Category(s): Therapeutics
|
|
Therapeutic Protection from Diet-Induced Obesity and Insulin Resistance Through Targeting of RP105/MD-1
Therapeutic Protection from
Diet-Induced Obesity and Insulin Resistance Through Targeting of
RP105/MD-1
CHMC Ref. Id: 2007-0803)
Overview:
Obesity is increasing in prevalence in adults and children, and authorities
view it as one of the most serious public health problems of the 21st century.
It is a primary risk factor for insulin resistance...
Published: 12/4/2012
Category(s): Therapeutics
|
|
Organ Transplant Solutions Comprising C5aRA Peptide
Organ Transplant Solutions
Comprising C5aRA Peptide
(CHMC Ref. Id: 2005-0107)
Overview:
According to the United Network for Organ Sharing (UNOS), there have been
over 400,000 organ transplants performed in the United States since 1988. In
addition, there are more than 100,000 people on the UNOS waiting list. One of
the biggest hurdles to overcome...
Published: 12/4/2012
Category(s): Therapeutics
|
|
Pharmaceutical Targeting of Eosinophils by CCR-3 Mediated Internalization
Pharmaceutical Targeting of
Eosinophils by CCR-3 Medicated Internalization
(CHMC Ref. Id: 1999-0210)
Overview:
Eosinophils normally appear in peripheral blood at a concentration of ~1-3%
of total leukocytes and their presence in tissue is primarily restricted to the
mucosa. However, in various disease states, such as eosinophilic esophagitis
(EoE),...
Published: 12/4/2012
Category(s): Therapeutics
|
|
Targeting Sox17 for the Treatment of Lung Injury
Targeting SOX17 for the
Treatment of Lung Injury
(CHMC Ref. Id: 2004-1102)
Overview:
The work associated with this technology demonstrates that SOX17 functions as
a key regulator in regeneration of the brochiolar epithelium after lung damage.
In addition, a role for bronchiolar epithelial cells as a source of progenitor
cells that can mediate lung...
Published: 12/4/2012
Category(s): Therapeutics
|
|
Directed Differentiation of Human Pluripotent Stem Cells into Intestinal Tissue in Culture
Directed Differentiation of
Human Pluripotent Stem Cells into Intestinal Tissue in Culture
(CHMC Ref. Id: 2010-0405)
Overview:
Using developmental paradigms, we have efficiently directed the
differentiation of human embryonic and induced pluripotent stem cells (PSCs)
into intestinal tissue in vitro. At the morphological and molecular level,
generation...
Published: 12/4/2012
Category(s): Therapeutics
|
|
Specific Protein Tyrosine Phosphatase Inhibitor for Cancer
Specific Protein Tyrosine
Phosphatase Inhibitor for Cancer
(CHMC Ref. Id: 2007-0514)
Overview:
Many protein tyrosine phosphatase (PTPs) are over-expressed in cancers. Often
they dephosphorylate and activate the oncogenic protein tyrosine kinase (PTK)
c-src, which accounts for 70% of the elevated PTK activity in breast
cancer. Thus, PTPs are emerging...
Published: 12/4/2012
Category(s): Therapeutics
|
|
Muteins of the C5a Anaphylatoxin and their Pharmaceutical Uses
Muteins of the C5a
Anaphylatoxin and Their Pharmaceutical Uses
(CHMC Ref. Id: 2004-0806)
Overview:
The complement system is a central part of innate immunity that is critical
to inflammation and host defense. Systemic activation or activation of
complement factor C5 in tissues results in the generation of the C5a
anaphylatoxin. Dr. Joerg Koehl...
Published: 12/4/2012
Category(s): Therapeutics
|
